Associations between Serum Vitamin D and Genetic …...5 92 Vitamin D is produced in the skin...
Transcript of Associations between Serum Vitamin D and Genetic …...5 92 Vitamin D is produced in the skin...
Associations between Serum Vitamin D and Genetic Variants inVitamin D Pathways and Age-Related Macular Degeneration in theEuropean Eye StudyMcKay, G. J., Young, I. S., McGinty, A., Bentham, G. C. G., Chakravarthy, U., Rahu, M., ... Fletcher, A. E.(2017). Associations between Serum Vitamin D and Genetic Variants in Vitamin D Pathways and Age-RelatedMacular Degeneration in the European Eye Study. Ophthalmology, 124(1), 90-96.https://doi.org/10.1016/j.ophtha.2016.09.007
Published in:Ophthalmology
Document Version:Peer reviewed version
Queen's University Belfast - Research Portal:Link to publication record in Queen's University Belfast Research Portal
Publisher rightsCopyright 2016 by the American Academy of OphthalmologyPublished by Elsevier Inc.. This manuscript version is made available under the CC-BY-NC-ND 4.0 licensehttp://creativecommons.org/licenses/by-nc-nd/4.0/ which permits distribution and reproduction for non-commercial purposes, provided theauthor and source are cited.
General rightsCopyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or othercopyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associatedwith these rights.
Take down policyThe Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made toensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in theResearch Portal that you believe breaches copyright or violates any law, please contact [email protected].
Download date:15. Mar. 2020
1
Associations between serum vitamin D and genetic variants in vitamin D pathways and age-1
related macular degeneration in the EUREYE study 2 3 Gareth J. McKay
1 PhD 4
Ian S. Young1 MD 5
Ann McGinty1
PhD 6 Graham C.G. Bentham
2 MA 7
Usha Chakravarthy3 MD
8
Mati Rahu4
PhD 9
Johan Seland5 MD 10
Gisele Soubrane6
MD 11 Laura Tomazzoli
7 MD 12
Fotis Topouzis8 MD 13
Jesus Vioque9MD 14
Paulus TVM de Jong10
MD, 15
Astrid E. Fletcher11
PhD 16 17 1
Centre for Public Health, Queen's University Belfast, UK 18 2
School of Environmental Sciences, University of East Anglia, UK 19 3
Centre for Experimental Medicine, Institute of Clinical Science, Queen's University Belfast, 20
UK 21 4 Department of Epidemiology and Biostatistics, National Institute for Health Development, 22
Tallinn, Estonia 23 5Eye Department, University of Bergen, Bergen, Norway 24
6 Department of Ophthalmology, Hotel Dieu de Paris, University Paris Descartes-1, France 25
7 Clinica Oculistica, Università degli Studi di Verona, Italy 26
8 Department of Ophthalmology, Aristotle University of Thessaloniki School of Medicine, 27
Greece 28 9 CIBER de Epidemiologia y Salud Publica, Universidad Miguel Hernandez, Alicante, Spain 29
10The Netherlands Institute of Neuroscience, AMC, Amsterdam, The Netherlands 30
11 Faculty of Epidemiology & Population Health, London School of Hygiene and Tropical 31
Medicine, UK
32 33
Corresponding author 34 Professor Astrid Fletcher 35 Faculty of Epidemiology & Population Health 36 London School of Hygiene and Tropical Medicine 37
United Kingdom 38 Email: [email protected] 39 Telephone: +44 (0) 207 927 2253 40
Fax: +44 (0) 207 580 6897 41 42 Fletcher, McGinty, Topouzis, Young report disclosures. 43 This article contains additional online-only material. The following should appear online-only: 44 Table 3,Table 4, Table 5,Table 6. 45 46
Revised manuscript - without track changes
2
Financial support: 47
EUREYE was supported by the European Commission Vth Framework (QLK6-CT-1999-48 02094) with additional funding for cameras provided by the Macular Disease Society UK, for 49 DNA extraction and genotyping (MRC Biomarkers Award G0601354), for dietary data by 50
Thomas Pocklington Trust and for vitamin D analyses by Guide Dogs for the Blind (OR2011-51 05d). M. Rahu is salaried by his home institute (grant IUT5-1 from the Estonian Research 52 Council).Additional funding in Alicante was received from the Fondo de Investigacion Sanitaria, 53 Madrid, Spain (grant nos. FIS 01/1692E, RCESP C 03/09), and Oficina de Ciencia y Tecnologia 54 Generalitat Valenciana, Valencia, Spain (grant no. CTGCA/2002/06). 55
56 The funding organizations had no role in the design or conduct of this research 57 58 Running head: Serum vitamin D, variants in vitamin D genes and age-related macular 59
degeneration 60
3
Abstract 61
Objective: To study associations between early and late age-related macular degeneration 62
(AMD) and the neovascular type of late AMD (nvAMD) with serum 25-hydroxy vitamin D 63
(25(OH)D) and genetic variants in vitamin D pathway genes. 64
Design: Population-based cross-sectional study in a random sample aged 65 and over from seven 65
European countries. 66
Participants: Of 4753 participants, 4496 (2028 men and 2468 women) ,mean age 73, provided a 67
usable blood sample; 2137 had no signs of AMD, 2209 had early AMD, 150 had late AMD of 68
which 104 nvAMD. 69
Methods: Participants were interviewed for smoking and alcohol use, brief medical history, 70
sunlight exposure and a dietary questionnaire, underwent color fundus photography and provided 71
a blood sample. Fundus images were graded using the modified International Classification 72
System for Age Related Maculopathy. 25(OH)D was measured by liquid chromatography-73
tandem mass spectrometry and categorized as deficient (< 30 nmol/L), insufficient (30–50 74
nmol/L), adequate (≥50 nmol/L). Genotyping was performed on a sub-sample of 1284 AMD 75
cases and controls for 93 SNPs from seven genes. Associations were investigated by linear or 76
logistic regression adjusted for potential confounders. 77
Main Outcome Measures: Adjusted odds ratio (AOR) for three outcomes (early AMD, late 78
AMD, nvAMD). 79
Results: No linear association was found with 25(OH)D and early or late AMD or nvAMD. 80
There was no association between insufficient or deficient status with early or late AMD. 81
Deficient status was associated with nvAMD (AOR = 1.27, 95% Confidence Interval 1.1-1.45, p 82
<0.0001). Significant (p<0.05) associations with 25(OH)D were found for SNPs in genes GC, 83
4
VDR ,CYP2R1, CYP27B1. Using a initial threshold of p<0.05, two SNPs (VDR) were associated 84
with early AMD, four SNPs (RXRA) and one (VDR) with nvAMD and one (RXRA), two (VDR) 85
and one (CYP2R1) with late AMD. After Bonferroni correction, no SNPS were associated with 86
early, late or nvAMD. 87
Conclusions: 25(OH)D deficient status was associated with nvAMD but the adjusted OR was 88
small and we cannot exclude residual confounding. The hypothesis of a causal association of 89
vitamin D with AMD is not supported by clear evidence for an association of vitamin D pathway 90
SNPs with early, late or nvAMD. 91
5
Vitamin D is produced in the skin following exposure to ultraviolet B (UVB) radiation as 92
vitamin D3 (cholecaliferol), and to a lesser extent, obtained from the diet (principally oily fish).1 93
The other natural source of vitamin D, Vitamin D2 (ergocalciferol) is found in a few foods and 94
provides a much smaller proportion of dietary vitamin D. Other sources of vitamin D include 95
supplements or, in some countries, fortified foods. In the body the biologically active metabolite 96
of vitamin D3, 1,25-dihydroxyvitamin D (1,25(OH)2D3) is distributed to the tissues and plays an 97
important role in a number of biological functions, including calcium homeostasis, immune 98
response and insulin metabolism.2 Serum 25-hydroxyvitamin D (25(OH)D) measures the total 99
circulating vitamin D (D2 and D3) and is used as a measure of vitamin D status. In countries of 100
the European Union where supplement use is relatively low and foods are not fortified, 25(OH)D 101
deficiency has been found in 13% of the overall population.3 In addition to environmental 102
factors, genetic variants influence 25(OH)D concentrations and single nucleotide polymorphisms 103
(SNPs) in a number of genes related to uptake and metabolism have been identified.4, 5
104
Recommendations for desirable levels of 25(OH)D of at least 50 nmol/L6 go beyond avoiding 105
deficiency to maximizing bone health. Vitamin D has also been postulated to influence disease 106
risk across a wide range of other conditions suggesting the potential benefit from increasing 107
vitamin D by diet or supplementation. However, a clear picture has not emerged. A large body 108
of evidence summarized in recent systematic reviews and meta analyses, based on nearly 300 109
observational studies and 200 randomized controlled trials (RCTs), showed reduced risks of all-110
cause mortality, cardiovascular disease (CVD) incidence and mortality in the observational 111
studies but not in the RCTs except for all-cause mortality.7, 8
112
113
6
Age related macular degeneration (AMD) is characterized by progressive degenerative changes 114
in the retina. Late stage AMD consists of neovascular AMD (nvAMD) and geographic atrophy 115
(GA). Hypotheses for an association of vitamin D with AMD are based on the anti-116
inflammatory role of vitamin D, identification of vitamin D receptors in retinal tissues,9, 10
and 117
the major role of inflammation and of complement-related genes and complement activation in 118
the development of AMD.11
CVD and risk factors for CVD such as smoking and diabetes are 119
additionally risk factors for nvAMD.12
There are inconsistent findings from studies investigating 120
the association of 25(OH)D with AMD.9, 13-17
Most studies lacked power to investigate late AMD 121
13-16 or reported an association with early
16 or late
17 AMD only in sub-groups (by gender or age). 122
Early AMD was associated with lower concentrations of 25(OH)D in some13,15
but not all 123
studies.14
Other studies investigating vitamin D and late AMD were based on diagnoses from 124
medical records 18-20
or from a case series.21
Two studies reported inconclusive findings for 125
SNPs in genes influencing 25(OH)D concentrations with early15
or late AMD9. In the absence of 126
clear evidence on this important question, we investigated associations between 25(OH)D and 127
SNPs in seven vitamin D related genes with AMD in the European Eye Study (EUREYE). 128
129
Methods 130
Participants were recruited by random sampling of the population aged 65 years and older in 131
seven centers across Europe: Bergen (Norway), Tallinn (Estonia), Belfast (UK), Paris (France), 132
Verona (Italy), Thessaloniki (Greece) and Alicante, (Spain). Participants were interviewed by 133
trained fieldworkers, underwent fundus photography, and provided blood samples. Information 134
collected at interview included education, smoking and alcohol use, a brief medical history, a 135
semi-quantitative food frequency questionnaire, and a detailed questionnaire to estimate 136
7
ultraviolet radiation exposure (UVR) (see below). Written informed consent was obtained from 137
all study participants. Institutional Review Board (IRB)/Ethics Committee approval was 138
obtained for each center. The study adhered to the tenets of the Declaration of Helsinki. 139
Fundus photography and grading 140
After pupillary dilation with tropicamide 0.5% and phenylephrine 5%, two 35° non-simultaneous 141
stereoscopic digitized color fundus images centered on the fovea were obtained of each eye. The 142
fundus images were sent to a single reading center (Erasmus University Rotterdam) and graded 143
using the International Classification System for Age-Related Maculopathy22
and then 144
categorized into five mutually exclusive grades. Grade 0 was defined as a macula free of drusen 145
or pigmentary irregularities or with hard drusen (< 63 µm) only. Early AMD was subdivided in 146
grade 1, defined as soft distinct drusen (≥ 63 µm) or pigmentary abnormalities, grade 2 as soft 147
indistinct drusen (≥ 125 µm) or reticular drusen only or soft distinct drusen (≥ 63 µm) with 148
pigmentary abnormalities, and grade 3 as soft indistinct drusen (≥ 125 µm) or reticular drusen 149
with pigmentary abnormalities. Grade 4 was defined as presence of either nvAMD (presence of 150
any of the following: serous or hemorrhagic retinal or retinal pigment epithelial detachment, 151
subretinal neovascular membrane, periretinal fibrous scar) or GA (well-demarcated area of 152
retinal pigment atrophy with visible choroidal vessels). 153
Measurement of UV exposure 154
Full details of UV measurement have been published previously23
. We used a detailed 155
questionnaire to ascertain lifetime residence and time spent outdoors (from age 14), for work 156
(including homecare), leisure and retirement up to current age. Information from the 157
questionnaire, residence calendar and geographical co-ordinates for residence were sent to the 158
University of East Anglia to estimate years of exposure for different wavelengths of UVR (UVA, 159
8
UVB and blue light) using published sources that take into account time of day, month, and 160
latitudinal variations. Personal adult lifetime UV exposure were estimated for each of the three 161
wavelengths of light and summed for a mean annual lifetime dose for all day exposures and for 162
exposures in the middle of the day. 163
Blood analyses 164
Non-fasting venous blood samples were separated within 4 hours of collection and serum was 165
stored at -20○C for up to 4 weeks before frozen samples were transferred to a single laboratory 166
(Queens University Belfast) for storage at -80○C. Antioxidant and cholesterol analyses were 167
carried out within 3 months of storage. Plasma lutein, zeaxanthin, beta cryptoxanthin, alpha and 168
beta-carotene, alpha and gamma tocopherol, lycopene and retinol were measured by reverse 169
phase high pressure liquid chromatography. Plasma vitamin C was measured using an enzyme-170
based assay in plasma stabilized with metaphosphoric acid. All assays were standardized against 171
appropriate National Institute of Standards and Technology (NIST) standard reference materials. 172
Serum cholesterol was measured using an enzymatic assay (Randox, Crumlin, UK) on a Cobas 173
FARA centrifugal analyzer (Roche Diagnostics, UK). Serum 25-hydroxy vitamin D2 and D3 174
(25(OH)D2 and 25(OH)D3) were measured by liquid chromatography-tandem mass spectrometry 175
(LC-MS/MS) 8 to 10 years after initial collection. 176
SNP selection and Genotyping 177
For reason of costs, genotyping was undertaken in a sub-sample of the main study. A random 178
sample of controls (AMD grade 0) was frequency matched on age (within a year), sex and center 179
with all cases of (i) late AMD, and (ii) all cases with early AMD grades 2 and 3. Cases with 180
AMD grade 1 were not investigated. Ninety-three common SNPs located across 7 genes 181
involved in the vitamin D metabolic pathway (GC (10), RXRA (14), CYP2R1 (7), DHCR7 (5), 182
9
VDR (29), CYP27B1 (7), CYP24A1 (21) were selected from Phase III, release 2 HapMap 183
(http://www.hapmap.org) CEPH data (Utah residents with ancestry in northern and western 184
Europe; CEU) using Haploview (http://www.broadinstitute.org/haploview) to determine linkage 185
disequilibrium. Tag SNPs were selected using multimarker tagging where r2>0.8 for all 186
downloaded SNPs with a minor allele frequency (MAF) ≥5%, genotype call rate ≥95%, and no 187
significant deviation from Hardy Weinberg equilibrium (HWE). Genotyping was performed by 188
KBiosciences (Hoddesdon, United Kingdom). Quality filters for exclusion of SNPs included call 189
rates below 95% and deviation from HWE (P<0.001). DNA samples were excluded if missing 190
genotypes exceeded 10%. Other quality control measures included duplicates on plates, random 191
sample allocation to plates, independent scoring of problematic genotypes by two individuals 192
and re-sequencing of selected DNAs to validate genotypes. KBiosciences quality control also 193
included validation of all SNP assays on a panel of 44 random Caucasian-derived samples plus 4 194
non-template (negative) controls. 195
Data processing and statistical analysis 196
Statistical analysis was carried out using Stata software version 13 (Stata Corp., College Station, 197
TX) and PLINK (version 1.07) under an additive genotypic model.24
We investigated total 198
25(OH)D i.e. 25(OH)D2 plus 25(OH)D3 as (i) a continuous variable and (ii) categorized by 199
clinical status based on expert guidelines as: deficient (< 30 nmol/L), insufficient (30–50 200
nmol/L), and adequate (≥50 nmol/L).6 We excluded extreme values of ≥150 nmol/L (n=17). 201
25(OH)D was normalized using a square root transformation due to a long right hand tail (110 202
participants had values ≥100 and <150 nmol/L). Dietary vitamin D was estimated using food 203
composition tables25
and adjusted for total energy intake.26
All day UVB exposures were square 204
root transformed and lutein concentrations log transformed. We ran preliminary regression 205
10
analyses to identify factors associated with 25(OH)D as possible confounders of any association 206
with AMD and carried out a similar analysis for vitamin D status. We used univariable and 207
confounder-adjusted logistic regression to investigate associations between 25(OH)D or vitamin 208
D status and early grades of AMD and nvAMD. We also present results for all late AMD 209
(nvAMD and GA combined) as numbers with GA were too small (n=46) to permit meaningful 210
separate analyses. Analyses took account of the study design by including study centre in 211
models and by use of robust errors in Stata.27
We report associations of individual SNPs with 212
early, late and nvAMD at a nominal significance of p<0.05. Since our a priori hypothesis of an 213
association between SNPs in vitamin D-related genes and AMD was based on previously 214
demonstrated associations of vitamin D genes with 25(OH)D,4 5 we applied a Bonferroni 215
correction based on the number of SNPs within each gene in the AMD analyses in preference to 216
a GWAS type correction for all 92 snps. We also investigated whether any association of 217
25(OH)D status and nvAMD or early AMD was modified by the main AMD genetic risk loci, 218
rs1061170 in CFH and rs10490924 in ARMS2,as has been reported previously.15
219
220
Results 221
Serum 25(OH)D 222
Of 4753 participants at the clinical examination, 4496 provided a usable blood sample for the 223
vitamin D assays. Of these 2137 had no signs of AMD, 2209 had early AMD; 1635 (grade 1), 224
460 (grade 2), 114 (grade 3), 46 (GA) and 104 nvAMD. The mean (standard deviation, SD) of 225
25(OH)D concentrations was 49 (23) nmol/L. The highest mean seasonally-adjusted 226
concentration was observed in the Bergen center (63 (20) nmol/L) compared to all other centers 227
with adjusted differences ranging from 20 nmol/L lower concentrations in Paris, approximately 228
11
15 nmol/L lower in Tallinn, Belfast, Verona and Thessaloniki, to 9 nmol/L in Alicante (all 229
comparisons p <0.0001). Vitamin D deficiency was found in 21% (n=944) and 32.8% (1475) 230
were classified as insufficient. Only 13.4% (604) had concentrations of 75 nmol/L or greater. A 231
large number of variables were independently associated with 25(OH)D. In multivariable 232
analyses adjusted for center and season, levels were lower with increasing age, in women, in 233
current smokers, participants with diabetes, and higher in those taking fish oil supplements, and 234
drinking alcohol at least weekly. 25(OH)D was associated with higher UVB exposure, dietary 235
vitamin D intake, serum cholesterol, and plasma concentrations of ascorbate, lutein (or 236
zeaxanthin), and retinol (all associations, p<0.05 or less). There was no association with 237
education. Lutein and zeaxanthin were highly correlated (r=0.85) and therefore associations with 238
25(OH)D were almost identical. The characteristics of people categorized by 25(OH)D status 239
are shown in Table 1 (univariable analyses). Proportionately fewer people classified as 240
insufficient or deficient took fish oil supplements or consumed oily fish at least weekly, were 241
less likely to be in the highest quartile of dietary vitamin D intake, or dietary docosahexaenoic 242
acid intake, and were more likely to be older or obese compared to those with sufficient levels. 243
Associations with AMD 244
Covariate-adjusted models showed no association of 25(OH)D with any grade of early AMD or 245
late or nvAMD (Table 2). 25(OH)D status was not associated with any grade of early or late 246
AMD (Table 2). For nvAMD, deficient status was associated with a covariate adjusted OR of 247
1.27, 95% confidence interval (1.11-1.45) p<0.0001. Although numbers with GA were small 248
there was no indication of increased odds for deficiency status (OR=0.82, 0.36- 1.89). We found 249
no significant interactions with rs1061170 or rs10490924 with 25(OH)D status and nvAMD 250
(p=0.32 and 0.30 respectively) or early AMD (p=0.28 and 0.11). 251
12
Genetic associations 252
Genotype data were available for 93 SNPs from 1284 participants selected for genetic analysis. 253
One SNP in GC was excluded for failing to meet the quality filters of call rates below 95% or 254
deviation from HWE (P<0.001). The average call rate for the remaining SNPs was 99.3%. No 255
participants were excluded due to insufficient genotype data. No duplicate inconsistencies were 256
observed. Results for all 92 SNPs and their age, sex and center adjusted association with 257
25(OH)D (additionally adjusted for season), early,late, nvAMD are provided in Tables 3-6 258
(available at http://www.aaojournal.org). Nominal significant results are summarized in 259
Table7. Our results confirmed that SNPs in GC (3), RXRA (1), CYP2R1 (2), VDR (1) and 260
CYP27B1 (1) were associated with 25(OH)D. Two SNPs both in VDR (rs11574026, rs4516035) 261
were significantly associated with early AMD. Five SNPs were significantly associated with 262
nvAMD: four in RXRA (rs11185644, rs12339187, rs10881582, rs3118536,) and one in VDR 263
(rs11574077). Analysis of late AMD identified four significantly associated SNPs following the 264
inclusion of participants with GA. These were rs3118536 in RXRA, rs10875693 and rs11574077 265
in VDR, and rs11023371 in CYP2R1. After applying Bonferroni corrections of p=0.004 for 14 266
RXRA SNPs and p=0.002 for 29 VDR SNPS, no SNPs were associated with early AMD, nvAMD 267
or late AMD. 268
269
Discussion 270
We found no linear association between 25(OH)D and early or nvAMD. 25(OH)D deficiency 271
status was associated with nvAMD, adjusted OR of 1.27. Insufficient 25(OH)D status was not 272
associated with nvAMD. 273
13
Few studies have investigated associations between 25(OH)D and late AMD with inconsistent 274
results. Several studies have used historical medical records and linked information on vitamin 275
D to a diagnosis of late AMD. No association was found with nvAMD in a Medicare study of 276
7000 people with a diagnosis of Vitamin D deficiency and matched controls followed for 3 277
years.18
Retrospective medical records identification of 146 nvAMD patients tested for vitamin 278
D compared with 100 age, sex and race matched controls with pseudophakia, reported an 279
adjusted OR of 0.37 (CI 0.19- 0.72) between the highest and lowest quintile of 25(OH)D.20
A 280
health records study in Israel of 9267 participants with a routine 25(OH)D measurement 281
identified 1045 individuals with a diagnosis of AMD (grade and severity not available) and 282
found no differences in 25(OH)D compared to non-AMD participants; results were not adjusted 283
for age although AMD cases were older than non-AMD.19
Using records of a mobile geriatric 284
clinic of 26 late AMD cases and 34 with no AMD signs, 25(OH)D deficiency was associated 285
with a 3 fold OR, 95% CI, 1-9, results were adjusted only for age, sex and season of blood 286
collection.28
287
An inverse association was found between early AMD and 25(OH)D in the US National Health 288
and Nutrition Examination survey (NHANES III)13
and in women aged < 75 years in the 289
Carotenoids in Age-Related Eye Disease Study (CAREDS study) but not in those aged 75 and 290
over.16
Neither study found an association with 25(OH) D and late AMD but the number of 291
cases evaluated was small. In the Korean National Health and Nutrition study there was no 292
association with early or late AMD overall; separate analyses by gender found reduced odds of 293
late AMD with increasing 25(OH)D in men but not in women.17
No association of 25(OH)D 294
concentrations categorized as deficient (<25 nmol/L) or insufficient (25–49 nmol/L) compared to 295
14
sufficient (≥50 nmol/L) with either early or late AMD, were observed in a small population 296
based study of elderly residents in France.14
297
In our study, 25(OH)D was measured in stored blood samples collected at the same time as the 298
ascertainment of AMD. We cannot therefore exclude the possibility of reverse causation i.e. that 299
nvAMD, directly or indirectly, influenced the 25(OH)D levels, for example as a result of 300
complement-related or other inflammatory effects.11
We had no information on co-morbidities 301
which may be either consequences of AMD such as depression and anxiety,29
low physical 302
activity30
or other age-related conditions associated with AMD such as cognitive impairment31, 32
303
or complement-related conditions such as diabetic nephropathy,33, 34
some of which have been 304
associated with 25(OH)D.7, 8
The conclusion of one substantial review of vitamin D and a wide 305
range of health outcomes highlighted a lack of highly convincing evidence for a clear role of 306
vitamin D for many health related outcomes in both randomized and observational studies.8 307
Furthermore, Autier and colleagues suggest that low 25(OH)D is a marker of ill health and that 308
inflammatory processes involved in disease manifestation reduce 25(OH)D, explaining why low 309
vitamin D status has been reported for a wide range of disorders7. Restoration of vitamin D 310
deficits due to ageing and lifestyle changes induced by ill health could explain why low-dose 311
supplementation may lead to slight gains in survival in the elderly. 312
Genetic variants in vitamin D pathway members are not subject to concerns of temporality and 313
confounding and therefore provide stronger evidence on the possible association of vitamin D 314
with AMD. SNPs in the CYP24A1 and VDR gene were identified in the discovery phase of a 315
family nvAMD study but in the replication component, only variants in CYP24A1 were found to 316
be associated.9 In the CAREDS study, SNPs in CYP2R1 and VDR but not CYP24A1 were 317
associated with early AMD.15
In our study, we found no significant associations between 318
15
variants in CYP2R1 and early AMD but a nominal association with two VDR SNPs. A VDR 319
SNP (rs11574077) was significantly associated with nvAMD in our study but this SNP was not 320
associated with nvAMD in a family study.9 We found the strongest evidence of nominal 321
association for SNPs located within the RXRA gene region (rs12339187, rs3118536, rs11185644, 322
rs10881582), although these did not withstand correction for multiple testing. A limitation of 323
our study was the small number of cases of early and nvAMD for investigation of genetic 324
associations. 325
Genetic determinants of vitamin D bioactivity have been identified previously in the genes 326
encoding VDR and the retinoic acid-X-receptor (RXRA), which forms a complex with 1,25 OH2 327
D bound to VDR and is recognized by vitamin D response elements on target genes.35
We 328
directly genotyped rs1570669 and rs2274130 in CYP24A1, together with rs927651 as a proxy for 329
rs1570670, rs2296239 and rs4809957, all SNPs in high linkage disequilibrium. We found no 330
evidence to support their previously reported association with AMD.13
In addition, previous 331
reports of VDR SNPs associated with AMD offer little support for our study findings and vice 332
versa,19
although lack of support may result from discrepancies in recruitment and composition, 333
study size and characterization of the AMD cases within each study. In contrast to a previous 334
finding we found no evidence that major AMD genetic risk variants (rs1061170 and rs10490924) 335
modified the association between 25(OH)D deficiency and early AMD and nvAMD.19
We did 336
not find a relationship with RXRA SNPs and 25(OH)D; however, a previous association with one 337
RXRA SNP (rs9409929) has been reported only with the metabolite 1,25 OH2 D but not the 338
circulating serum level.36
It is possible that the nominal association we report between RXRA 339
variants and nvAMD may not relate to vitamin D. RXRA receptors are involved in a large 340
number of pathways other than those related to vitamin D including, of relevance to AMD, 341
16
glucose and lipid metabolism37
and the omega 3 fatty acid, docosahexaenoic acid.38
Previously 342
reported genome wide association data evaluated several SNPs across the RXRA gene in 2157 343
mixed early and late AMD cases and 1150 controls (http://www.ncbi.nlm.nih.gov/gap) including 344
rs10881582, p=0.15, but no evidence of association was found.39
345
We conclude therefore that the hypothesis of a causal association of vitamin D with AMD is not 346
supported by clear evidence for an association of vitamin D pathway SNPs with early, late or 347
nvAMD. Moreover concerns about residual confounding and reverse causation make it unlikely 348
that there is an association between vitamin D deficiency and AMD. 349
350
17
References 351
1. Bendik I, Friedel A, Roos FF, et al. Vitamin D: a critical and essential micronutrient for 352
human health. Front Physiol 2014;5:248. 353
2. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266-81. 354
3. Cashman KD, Dowling KG, Skrabakova Z, et al. Vitamin D deficiency in Europe: 355
pandemic? Am J Clin Nutr 2016;103:1033-44 356
4. Ahn J, Yu K, Stolzenberg-Solomon R, et al. Genome-wide association study of 357
circulating vitamin D levels. Hum Mol Genet 2010;19:2739-45. 358
5. Wang TJ, Zhang F, Richards JB, et al. Common genetic determinants of vitamin D 359
insufficiency: a genome-wide association study. Lancet 2010;376:180-8. 360
6. Institute of Medicine. Dietary Reference Intakes for Calcium and Vitamin D. 361
Washington, DC: T he National Academies Press, 2011. 362
7. Autier P, Boniol M, Pizot C, Mullie P. Vitamin D status and ill health: a systematic 363
review. Lancet Diabetes Endocrinol 2014;2:76-89. 364
8. Theodoratou E, Tzoulaki I, Zgaga L, Ioannidis JP. Vitamin D and multiple health 365
outcomes: umbrella review of systematic reviews and meta-analyses of observational 366
studies and randomised trials. BMJ 2014;348:g2035. 367
9. Morrison MA, Silveira AC, Huynh N, et al. Systems biology-based analysis implicates a 368
novel role for vitamin D metabolism in the pathogenesis of age-related macular 369
degeneration. Hum Genomics 2011;5:538-68. 370
10. Reins RY, McDermott AM. Vitamin D: Implications for ocular disease and therapeutic 371
potential. Exp Eye Res 2015;134:101-10. 372
11. Anderson DH, Radeke MJ, Gallo NB, et al. The pivotal role of the complement system in 373
aging and age-related macular degeneration: hypothesis re-visited. Prog Retin Eye Res 374
2010;29:95-112. 375
12. Chakravarthy U, Wong T, Fletcher A, et al. Clinical risk factors for age-related macular 376
degeneration: a systematic review and meta-analysis. BMC Ophthalmology 2010;10:31. 377
13. Parekh N, Chappell RJ, Millen AE, et al. Association between vitamin D and age-related 378
macular degeneration in the Third National Health and Nutrition Examination Survey, 379
1988 through 1994. Arch Ophthalmol 2007;125:661-9. 380
18
14. Cougnard-Gregoire A, Merle BM, Korobelnik JF, et al. Vitamin D Deficiency in 381
Community-Dwelling Elderly Is Not Associated with Age-Related Macular 382
Degeneration. J Nutr 2015;145:1865-72. 383
15. Millen AE, Meyers KJ, Liu Z, et al. Association Between Vitamin D Status and Age-384
Related Macular Degeneration by Genetic Risk. JAMA Ophthalmol 2015;133:1171-9. 385
16. Millen AE, Voland R, Sondel SA, et al. Vitamin D status and early age-related macular 386
degeneration in postmenopausal women. Arch Ophthalmol 2011;129:481-9. 387
17. Kim EC, Han K, Jee D. Inverse relationship between high blood 25-hydroxyvitamin D 388
and late stage of age-related macular degeneration in a representative Korean population. 389
Invest Ophthalmol Vis Sci 2014;55:4823-31. 390
18. Day S, Acquah K, Platt A, et al. Association of vitamin D deficiency and age-related 391
macular degeneration in medicare beneficiaries. Arch Ophthalmol 2012;130:1070-1. 392
19. Golan S, Shalev V, Treister G, et al. Reconsidering the connection between vitamin D 393
levels and age-related macular degeneration. Eye (Lond) 2011;25:1122-9. 394
20. Itty S, Day S, Lyles KW, et al. Vitamin D deficiency in neovascular versus 395
nonneovascular age-related macular degeneration. Retina 2014;34:1779-86. 396
21. Singh A, Falk MK, Subhi Y, Sorensen TL. The association between plasma 25-397
hydroxyvitamin D and subgroups in age-related macular degeneration: a cross-sectional 398
study. PLoS One 2013;8:e70948. 399
22. Bird AC, Bressler NM, Bressler SB, et al. An international classification and grading 400
system for age-related maculopathy and age-related macular degeneration. The 401
International ARM Epidemiological Study Group. Surv Ophthalmol 1995;39:367-74. 402
23. Fletcher AE, Bentham GC, Agnew M, et al. Sunlight exposure, antioxidants, and age-403
related macular degeneration. Arch Ophthalmol 2008;126:1396-403. 404
24. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome 405
association and population-based linkage analyses. Am J Hum Genet 2007;81:559-75. 406
25. Holland B, Welch A, Unwin I, et al. McCance and Widdowson's composition of foods. 407
London: Her Majesty's Stationery Office, 1991. 408
26. Willett WC, Howe GR, Kushi LH. Adjustment for total energy intake in epidemiologic 409
studies. Am J Clin Nutr 1997;65:1220S-8. 410
27. Williams RL. A note on robust variance estimation for cluster-correlated data. . 411
Biometrics 2000;56:645-6. 412
19
28. Graffe A, Milea D, Annweiler C, et al. Association between hypovitaminosis D and late 413
stages of age-related macular degeneration: a case-control study. J Am Geriatr Soc, 414
2012;60:1367-9 415
29. Cimarolli VR, Casten RJ, Rovner BW, et al. Anxiety and depression in patients with 416
advanced macular degeneration: current perspectives. Clin Ophthalmol 2016;10:55-63. 417
30. Loprinzi PD, Swenor BK, Ramulu PY. Age-Related Macular Degeneration Is Associated 418
with Less Physical Activity among US Adults: Cross-Sectional Study. PLoS One 419
2015;10:e0125394. 420
31. Clemons TE, Rankin MW, McBee WL, Age-Related Eye Disease Study Research G. 421
Cognitive impairment in the Age-Related Eye Disease Study: AREDS report no. 16. 422
Arch Ophthalmol 2006;124:537-43. 423
32. Pham TQ, Kifley A, Mitchell P, Wang JJ. Relation of age-related macular degeneration 424
and cognitive impairment in an older population. Gerontology 2006;52:353-8. 425
33. Nitsch D, Douglas I, Smeeth L, Fletcher A. Age-related macular degeneration and 426
complement activation-related diseases: a population-based case-control study. 427
Ophthalmology 2008;115:1904-10. 428
34. Wong CW, Wong TY, Cheng CY, Sabanayagam C. Kidney and eye diseases: common 429
risk factors, etiological mechanisms, and pathways. Kidney Int 2014;85:1290-302. 430
35. Karami S, Brennan P, Navratilova M, et al. Vitamin d pathway genes, diet, and risk of 431
renal cell carcinoma. Int J Endocrinol 2010:879362. 432
36. Hibler EA, Jurutka PW, Egan JB, et al. Association between polymorphic variation in 433
VDR and RXRA and circulating levels of vitamin D metabolites. J Steroid Biochem Mol 434
Biol 2010;121:438-41. 435
37. Ahuja HS, Szanto A, Nagy L, Davies PJ. The retinoid X receptor and its ligands: 436
versatile regulators of metabolic function, cell differentiation and cell death. J Biol Regul 437
Homeost Agents 2003;17:29-45. 438
38. Lengqvist J, Mata De Urquiza A, Bergman AC, et al. Polyunsaturated fatty acids 439
including docosahexaenoic and arachidonic acid bind to the retinoid X receptor alpha 440
ligand-binding domain. Mol Cell Proteomics 2004;3:692-703. 441
39. Chen W, Stambolian D, Edwards AO, et al. Genetic variants near TIMP3 and high-442
density lipoprotein-associated loci influence susceptibility to age-related macular 443
degeneration. Proc Natl Acad Sci U S A 2010;107:7401-6. 444
445
Table 1. Characteristics of participants by vitamin D status
1 Mean (SD)
2 % (n)
3 Median, IQR (interquartile range)
4 Energy adjusted
5 p trend based on log lutein
Serum 25(OH)D status
nmol/L)
Sufficient
>50 (nmol/L)
Insufficient
≥30<50 (nmol/L)
Deficient
<30 (nmol/L)
N 2077 1475 944 p trend
Serum 25(OH)D (nmol/L) 1
70.2 (16.0) 39.9 (5.7) 21.2 (5.9)
Age1 72.6 (5.4) 73.3 (5.7) 74.5 (6.0) <0.0001
Women 2
47.9 (1055) 53.7 (823) 61.7 (590) 0.11
Education (lowest tertile of years)2
37.4 (769) 36.5 (561) 39.5 (380) 0.42
Ever smoker 2
49.2 (1020) 44.8 (681) 43.3 (414) 0.13
Alcohol at least weekly2
52.2(903) 44.4 (555) 44.0 (374) 0.18
Annual UVB exposure (MED)3,5
237 (123-393) 229 (112-412) 202 (69-380) 0.17
Obese2 (BMI ≥30) 32.1 (645) 40.4 (567) 40.7 (352) 0.05
Diabetes2
12.9 (218) 17.9 (219) 16.7 (147) 0.02
CVD2 12.5 (268) 13.6 (215) 14.3 (142) 0.29
Fish oil supplement use2
8.2 (381) 3.9 (109) 1.5 (22) 0.22
Blood measures µmol/L
Cholesterol1 5.8 (1.1) 5.6 (1.1) 5.6 (1.0) 0.12
Vitamin C1, 48.4 (24.8) 42.2 (25.4) 40.6 (25.6) 0.02
Lutein3,5
1.26 (0.47-2.79) 0.99 (0.46-2.42) 0.90 (0.46-2.42) 0.05
Alpha- tocopherol1 30.6 (7.0) 30.5 (7.0) 29.9 (6.7) 0.43
Retinol1 2.23 (0.77) 2.19 (0.79) 2.18 (0.74) 0.36
Dietary variables
≥ 1 Oily fish serving per week2
45.8 (892) 36.7 (522) 27.5 (254) 0.02
Vitamin D4 (highest quartile) 30.9 (593) 24.7 (355) 18.2 (153) 0.01
DHA4 (highest quartile) 33.7 (617) 25.9 (350) 17.9 (150) 0.01
Table 1
Table 2. Association of early, late and neovascular AMD with (i) 25(OH)D (nmol/L) distribution (ii) Vitamin D status
a Square root transformed serum 25(OH)D nmol/L
bOdds ratio (OR) and 95% Confidence Interval (95% CI)
cAdjusted for age, sex, center, season, smoking, CVD, diabetes, alcohol consumption, BMI, plasma cholesterol, alpha-tocopherol,
retinol ,lutein, ascorbate.
d Odds ratio (OR) per unit increase of square root transformed serum 25(OH)D
Serum 25(OH)D
(nmol/L)a
Sufficient
>50 nmol/L
Insufficient
≥30 -<50 nmol/L Deficient
<30 nmol/L
OR (95% CI)b,c,d
p Reference OR (95% CI)b,c
p OR (95% CI)b,c
p
Early AMD
Grade 1 0.98 (0.94-1.01) 0.24 1 0.98 (0.88-1.10) 0.78 0.97 (0.79-1.18) 0.73
Grade 2 1.04 (0.93-1.17) 0.36 1 0.94 (0.71-1.23) 0.65 0.88 (0.54-1.45) 0.62
Grade 3 1.03 (0.89-1.20) 0.65 1 0.65 (0.38-1.10) 0.11 1.17 (0.84-1.64) 0.36
Late AMD 1.02 (0.94-1,11) 0.59 1 0.76 (0.48-1.20) 0.19 1.21 (0.88-1.68) 0.19
Neovascular AMD 1.02 (0.95 -1.08) 0.64 1 0.92 (0.57-1.48) 0.73 1.27 (1.11-1.45) <0.0001
Table 2
Table 7. Genetic association of SNPs with P<0.05 for (a) serum 25(OH)D (b) early AMD,
(c) late AMD and (d) neovascular AMD
(a) Vitamin D CHR SNP Gene BP BETA (SE)a P
4 rs2298850 GC 72833131 -0.414 (0.116) <0.001
4 rs1155563 GC 72862352 -0.276 (0.116) 0.018
4 rs11939173 GC 72891022 -0.242 (0.106) 0.023
9 rs11185644 RXRA 136350684 -0.277 (0.133) 0.038
11 rs10832306 CYP2R1 14813670 -0.342 (0.169) 0.043
11 rs7935792 CYP2R1 14866037 -0.556 (0.206) 0.007
12 rs2239186 VDR 46555677 -0.390 (0.125) 0.002
12 rs4760169 CYP27B1 56405114 -0.483 (0.167) 0.004
CHR SNP Gene BP OR (95% CI)b P
(b) Early AMD 12 rs11574026 VDR 46574513 0.74 (0.56-0.98) 0.03
12 rs4516035 VDR 46586093 1.21 (1.02-1.44) 0.03
(c) Late AMD 9 rs3118536 RXRA 136448283 0.60 (0.41-0.90) 0.01
12 rs10875693 VDR 46555917 1.44 (1.08-1.93) 0.01
12 rs11574077 VDR 46539194 0.32 (0.12-0.84) 0.02
11 rs11023371 CYP2R1 14852847 1.67 (1.01-2.74) 0.04
(d) nvAMD 9 rs11185644 RXRA 136350684 0.53 (0.32-0.87) 0.01
9 rs12339187 RXRA 136369148 0.54 (0.33-0.88) 0.01
9 rs10881582 RXRA 136395899 0.64 (0.43-0.97) 0.04
9 rs3118536 RXRA 136448283 0.54 (0.33-0.87) 0.01
12 rs11574077 VDR 46539194 0.18 (0.04-0.76) 0.02
a Regression coefficient (Beta) of square root transformed 25(OH)D and Standard error (SE)
adjusted for age, sex ,center and season.
b Odds Ratio (OR) and 95% Confidence Interval (CI) for early, late and nvAMD adjusted for
age, sex, center
Abbreviations: AMD, age related macular degeneration; nvAMD, neovascular age related
macular degeneration; CHR, chromosome; SNP, single nucleotide polymorphism; BP, base pair;
Table 7
Table 3 (online supplement). Genetic association of SNPs with vitamin D concentrations adjusted for age, sex, center and season in participants with no AMD
CHR SNP Gene BP BETA (SE) P
4 rs12512631 GC 72820195 0.118 (0.106) 0.268
4 rs705117 GC 72826979 0.248 (0.146) 0.090
4 rs2298850 GC 72833131 -0.414 (0.116) <0.001
4 rs222020 GC 72855136 0.053 (0.146) 0.716
4 rs1491718 GC 72860143 -0.118 (0.170) 0.487
4 rs1155563 GC 72862352 -0.276 (0.116) 0.018
4 rs16847050 GC 72886195 -0.009 (0.157) 0.956
4 rs1565572 GC 72889055 0.056 (0.132) 0.670
4 rs11939173 GC 72891022 -0.242 (0.106) 0.023
9 rs11185644 RXRA 136350684 -0.277 (0.133) 0.038
9 rs12339187 RXRA 136369148 -0.133 (0.131) 0.310
9 rs914853 RXRA 136378984 0.065 (0.112) 0.560
9 rs11185659 RXRA 136383204 0.049 (0.121) 0.688
9 rs10881582 RXRA 136395899 -0.149 (0.120) 0.214
9 rs7039190 RXRA 136406525 -0.246 (0.254) 0.334
9 rs11103473 RXRA 136427450 -0.193 (0.112) 0.084
9 rs11103482 RXRA 136427681 0.127 (0.170) 0.455
9 rs3118536 RXRA 136448283 -0.254 (0.130) 0.052
9 rs4240705 RXRA 136451221 -0.029 (0.109) 0.789
9 rs6537944 RXRA 136452649 0.337 (0.200) 0.092
9 rs3118571 RXRA 136457999 -0.026 (0.107) 0.805
9 rs4842196 RXRA 136473049 0.224 (0.121) 0.065
9 rs3118526 RXRA 136477178 0.274 (0.149) 0.065
11 rs7117967 CYP2R1 14782654 -0.185 (0.195) 0.343
11 rs12419657 CYP2R1 14783385 0.324 (0.166) 0.051
11 rs1037379 CYP2R1 14809360 -0.072 (0.110) 0.510
11 rs10832306 CYP2R1 14813670 -0.342 (0.169) 0.043
11 rs1496167 CYP2R1 14833083 0.053 (0.112) 0.638
11 rs11023371 CYP2R1 14852847 0.142 (0.215) 0.510
11 rs7935792 CYP2R1 14866037 -0.556 (0.206) 0.007
11 rs1792284 DHCR7 70812614 -0.140 (0.119) 0.240
11 rs4316537 DHCR7 70832777 -0.277 (0.211) 0.191
11 rs12785878 DHCR7 70845097 -0.178 (0.114) 0.118
11 rs949178 DHCR7 70877968 0.046 (0.188) 0.808
11 rs7950649 DHCR7 70898979 0.026 (0.153) 0.864
12 rs11574143 VDR 46521184 0.233 (0.171) 0.172
12 rs731236 VDR 46525024 -0.137 (0.109) 0.209
12 rs7975232 VDR 46525104 0.015 (0.103) 0.886
12 rs1544410 VDR 46526102 -0.134 (0.108) 0.216
12 rs11168268 VDR 46538079 -0.064 (0.104) 0.535
Supplemental Table 3 - Online Only
12 rs11574077 VDR 46539194 -0.398 (0.242) 0.101
12 rs2239182 VDR 46541678 -0.076 (0.101) 0.450
12 rs2107301 VDR 46541837 0.124 (0.110) 0.260
12 rs2283342 VDR 46542126 -0.261 (0.136) 0.055
12 rs2239179 VDR 46544033 -0.163 (0.103) 0.115
12 rs12717991 VDR 46545393 0.032 (0.100) 0.747
12 rs886441 VDR 46549231 0.154 (0.130) 0.237
12 rs2189480 VDR 46550095 -0.152 (0.107) 0.156
12 rs3819545 VDR 46551273 0.089 (0.106) 0.399
12 rs2239186 VDR 46555677 -0.390 (0.125) 0.002
12 rs10875693 VDR 46555917 0.052 (0.113) 0.646
12 rs6580642 VDR 46556863 0.074 (0.131) 0.573
12 rs2254210 VDR 46559981 0.032 (0.104) 0.755
12 rs2238136 VDR 46563980 -0.059 (0.113) 0.605
12 rs2853564 VDR 46564754 0.006 (0.103) 0.955
12 rs4760648 VDR 46566932 -0.043 (0.101) 0.674
12 rs11574027 VDR 46573640 0.013 (0.391) 0.974
12 rs11574026 VDR 46574513 0.009 (0.164) 0.957
12 rs4760655 VDR 46580398 0.021 (0.108) 0.845
12 rs7136534 VDR 46580893 -0.075 (0.126) 0.549
12 rs11574024 VDR 46582488 0.161 (0.169) 0.342
12 rs4516035 VDR 46586093 -0.092 (0.105) 0.380
12 rs11168302 VDR 46598520 -0.097 (0.354) 0.784
12 rs10875702 VDR 46599285 0.060 (0.130) 0.646
12 rs2269720 CYP27B1 56404515 0.028 (0.115) 0.805
12 rs4760169 CYP27B1 56405114 -0.483 (0.167) 0.004
12 rs10877011 CYP27B1 56411259 0.046 (0.110) 0.677
12 rs12368653 CYP27B1 56419523 -0.072 (0.103) 0.487
12 rs1048691 CYP27B1 56439215 -0.103 (0.130) 0.429
12 rs4646537 CYP27B1 56443548 0.080 (0.306) 0.793
12 rs1021469 CYP27B1 56494431 -0.019 (0.111) 0.863
20 rs2762932 CYP24A1 52201798 0.138 (0.142) 0.332
20 rs6068810 CYP24A1 52202758 -0.087 (0.266) 0.744
20 rs11907350 CYP24A1 52203846 -0.062 (0.295) 0.832
20 rs927650 CYP24A1 52206148 -0.004 (0.101) 0.971
20 rs927651 CYP24A1 52206303 -0.036 (0.123) 0.770
20 rs6097809 CYP24A1 52206917 -0.281 (0.217) 0.196
20 rs1570669 CYP24A1 52207834 -0.039 (0.108) 0.718
20 rs2274130 CYP24A1 52208008 -0.046 (0.123) 0.708
20 rs6127119 CYP24A1 52212489 -0.045 (0.130) 0.730
20 rs6068816 CYP24A1 52214498 -0.043 (0.182) 0.813
20 rs3787555 CYP24A1 52216098 -0.008 (0.118) 0.945
20 rs3787557 CYP24A1 52216542 0.016 (0.152) 0.915
20 rs2762941 CYP24A1 52217059 0.004 (0.110) 0.972
20 rs2181874 CYP24A1 52217885 -0.095 (0.121) 0.433
20 rs4809959 CYP24A1 52219266 0.056 (0.101) 0.582
20 rs4809960 CYP24A1 52219480 0.015 (0.124) 0.905
20 rs2296241 CYP24A1 52219626 -0.059 (0.102) 0.563
20 rs2245153 CYP24A1 52219813 -0.003 (0.133) 0.982
20 rs2585428 CYP24A1 52220304 0.084 (0.105) 0.420
20 rs6022999 CYP24A1 52221420 0.038 (0.120) 0.754
20 rs2248359 CYP24A1 52224925 0.045 (0.107) 0.677
Abbreviations: CHR, chromosome; SNP, single nucleotide polymorphism; BP, base pair; SE,
standard error; BETA, beta coefficient; P, P value.
Table 4 (online supplement). Genetic association of SNPs with early AMD adjusted for age, sex and
center
CHR SNP Gene BP OR (95% CI) P
4 rs12512631 GC 72820195 0.92 (0.77-1.09) 0.34
4 rs705117 GC 72826979 1.09 (0.86-1.38) 0.47
4 rs2298850 GC 72833131 0.99 (0.82-1.19) 0.91
4 rs222020 GC 72855136 1.05 (0.83-1.32) 0.69
4 rs1491718 GC 72860143 0.97 (0.74-1.27) 0.81
4 rs1155563 GC 72862352 0.98 (0.81-1.19) 0.85
4 rs16847050 GC 72886195 1.01 (0.79-1.30) 0.92
4 rs1565572 GC 72889055 1.13 (0.92-1.39) 0.24
4 rs11939173 GC 72891022 1.07 (0.90-1.26) 0.45
9 rs11185644 RXRA 136350684 1.09 (0.88-1.35) 0.43
9 rs12339187 RXRA 136369148 0.99 (0.80-1.23) 0.93
9 rs914853 RXRA 136378984 1.12 (0.93-1.33) 0.24
9 rs11185659 RXRA 136383204 0.98 (0.81-1.20) 0.87
9 rs10881582 RXRA 136395899 1.05 (0.86-1.27) 0.65
9 rs7039190 RXRA 136406525 1.24 (0.83-1.85) 0.30
9 rs11103473 RXRA 136427450 1.06 (0.89-1.26) 0.51
9 rs11103482 RXRA 136427681 1.15 (0.88-1.51) 0.30
9 rs3118536 RXRA 136448283 0.92 (0.74-1.14) 0.46
9 rs4240705 RXRA 136451221 0.97 (0.81-1.15) 0.72
9 rs6537944 RXRA 136452649 1.17 (0.85-1.60) 0.34
9 rs3118571 RXRA 136457999 0.97 (0.82-1.16) 0.76
9 rs4842196 RXRA 136473049 0.96 (0.79-1.16) 0.65
9 rs3118526 RXRA 136477178 0.88 (0.69-1.13) 0.31
11 rs7117967 CYP2R1 14782654 1.33 (0.99-1.78) 0.06
11 rs12419657 CYP2R1 14783385 0.88 (0.67-1.15) 0.35
11 rs1037379 CYP2R1 14809360 0.95 (0.80-1.13) 0.59
11 rs10832306 CYP2R1 14813670 1.26 (0.98-1.64) 0.07
11 rs1496167 CYP2R1 14833083 0.98 (0.82-1.18) 0.85
11 rs11023371 CYP2R1 14852847 1.21 (0.86-1.69) 0.28
11 rs7935792 CYP2R1 14866037 1.28 (0.92-1.76) 0.14
11 rs1792284 DHCR7 70812614 1.05 (0.86-1.27) 0.64
11 rs4316537 DHCR7 70832777 1.00 (0.72-1.40) 0.98
11 rs12785878 DHCR7 70845097 1.06 (0.88-1.27) 0.55
11 rs949178 DHCR7 70877968 1.00 (0.74-1.37) 0.99
11 rs7950649 DHCR7 70898979 1.06 (0.83-1.35) 0.66
12 rs11574143 VDR 46521184 1.06 (0.82-1.39) 0.65
12 rs731236 VDR 46525024 0.94 (0.79-1.12) 0.49
12 rs7975232 VDR 46525104 1.01 (0.85-1.19) 0.92
12 rs1544410 VDR 46526102 0.95 (0.80-1.13) 0.54
12 rs11168268 VDR 46538079 1.08 (0.91-1.27) 0.38
12 rs11574077 VDR 46539194 0.87 (0.58-1.30) 0.48
Supplemental Table 4 - Online Only
12 rs2239182 VDR 46541678 1.12 (0.95-1.32) 0.18
12 rs2107301 VDR 46541837 0.89 (0.74-1.07) 0.21
12 rs2283342 VDR 46542126 1.08 (0.86-1.34) 0.51
12 rs2239179 VDR 46544033 1.06 (0.90-1.26) 0.48
12 rs12717991 VDR 46545393 0.95 (0.80-1.11) 0.51
12 rs886441 VDR 46549231 0.94 (0.76-1.16) 0.58
12 rs2189480 VDR 46550095 0.99 (0.83-1.17) 0.90
12 rs3819545 VDR 46551273 0.97 (0.82-1.16) 0.76
12 rs2239186 VDR 46555677 1.05 (0.86-1.29) 0.63
12 rs10875693 VDR 46555917 1.14 (0.96-1.36) 0.14
12 rs6580642 VDR 46556863 0.87 (0.70-1.09) 0.22
12 rs2254210 VDR 46559981 1.13 (0.96-1.34) 0.14
12 rs2238136 VDR 46563980 0.91 (0.75-1.10) 0.32
12 rs2853564 VDR 46564754 1.10 (0.93-1.30) 0.26
12 rs4760648 VDR 46566932 0.97 (0.82-1.14) 0.68
12 rs11574027 VDR 46573640 0.93 (0.49-1.77) 0.83
12 rs11574026 VDR 46574513 0.74 (0.56-0.98) 0.03
12 rs4760655 VDR 46580398 0.93 (0.78-1.11) 0.44
12 rs7136534 VDR 46580893 0.96 (0.79-1.18) 0.72
12 rs11574024 VDR 46582488 0.78 (0.58-1.04) 0.09
12 rs4516035 VDR 46586093 1.21 (1.02-1.44) 0.03
12 rs11168302 VDR 46598520 0.92 (0.51-1.65) 0.78
12 rs10875702 VDR 46599285 0.85 (0.69-1.05) 0.14
12 rs2269720 CYP27B1 56404515 1.08 (0.90-1.30) 0.41
12 rs4760169 CYP27B1 56405114 0.97 (0.74-1.28) 0.83
12 rs10877011 CYP27B1 56411259 0.95 (0.80-1.14) 0.60
12 rs12368653 CYP27B1 56419523 1.02 (0.87-1.21) 0.79
12 rs1048691 CYP27B1 56439215 1.11 (0.90-1.36) 0.35
12 rs4646537 CYP27B1 56443548 1.35 (0.85-2.14) 0.20
12 rs1021469 CYP27B1 56494431 1.05 (0.87-1.25) 0.63
20 rs2762932 CYP24A1 52201798 0.92 (0.73-1.16) 0.47
20 rs6068810 CYP24A1 52202758 1.26 (0.83-1.91) 0.28
20 rs11907350 CYP24A1 52203846 1.15 (0.73-1.83) 0.55
20 rs927650 CYP24A1 52206148 0.98 (0.83-1.15) 0.77
20 rs927651 CYP24A1 52206303 1.05 (0.86-1.28) 0.65
20 rs6097809 CYP24A1 52206917 1.08 (0.77-1.52) 0.65
20 rs1570669 CYP24A1 52207834 1.02 (0.86-1.22) 0.80
20 rs2274130 CYP24A1 52208008 1.04 (0.86-1.27) 0.68
20 rs6127119 CYP24A1 52212489 1.09 (0.89-1.34) 0.39
20 rs6068816 CYP24A1 52214498 0.99 (0.74-1.32) 0.93
20 rs3787555 CYP24A1 52216098 0.94 (0.77-1.13) 0.49
20 rs3787557 CYP24A1 52216542 0.87 (0.68-1.12) 0.29
20 rs2762941 CYP24A1 52217059 0.97 (0.81-1.15) 0.71
20 rs2181874 CYP24A1 52217885 1.02 (0.84-1.24) 0.83
20 rs4809959 CYP24A1 52219266 0.88 (0.75-1.04) 0.13
20 rs4809960 CYP24A1 52219480 0.97 (0.79-1.18) 0.73
20 rs2296241 CYP24A1 52219626 0.91 (0.77-1.07) 0.27
20 rs2245153 CYP24A1 52219813 0.98 (0.79-1.22) 0.84
20 rs2585428 CYP24A1 52220304 1.13 (0.95-1.33) 0.16
20 rs6022999 CYP24A1 52221420 1.08 (0.89-1.31) 0.45
20 rs2248359 CYP24A1 52224925 1.15 (0.97-1.37) 0.11
Abbreviations: CHR, chromosome; SNP, single nucleotide polymorphism; BP, base pair; P, P
value; OR, odds ratio; CI, confidence intervals.
Table 5 (online supplement). Genetic association of SNPs with late AMD adjusted for age, sex and
center
CHR SNP Gene BP OR (95% CI) P
4 rs12512631 GC 72820195 1.03 (0.79-1.36) 0.81
4 rs705117 GC 72826979 0.88 (0.58-1.32) 0.53
4 rs2298850 GC 72833131 1.06 (0.78-1.44) 0.72
4 rs222020 GC 72855136 0.81 (0.54-1.21) 0.31
4 rs1491718 GC 72860143 0.92 (0.59-1.44) 0.72
4 rs1155563 GC 72862352 1.05 (0.77-1.43) 0.77
4 rs16847050 GC 72886195 0.98 (0.65-1.49) 0.93
4 rs1565572 GC 72889055 0.98 (0.69-1.40) 0.91
4 rs11939173 GC 72891022 1.02 (0.77-1.34) 0.89
9 rs11185644 RXRA 136350684 0.70 (0.47-1.03) 0.07
9 rs12339187 RXRA 136369148 0.69 (0.47-1.01) 0.06
9 rs914853 RXRA 136378984 0.87 (0.64-1.18) 0.38
9 rs11185659 RXRA 136383204 0.76 (0.54-1.08) 0.12
9 rs10881582 RXRA 136395899 0.76 (0.55-1.07) 0.11
9 rs7039190 RXRA 136406525 1.20 (0.63-2.30) 0.58
9 rs11103473 RXRA 136427450 0.74 (0.55-1.00) 0.06
9 rs11103482 RXRA 136427681 1.05 (0.68-1.63) 0.81
9 rs3118536 RXRA 136448283 0.60 (0.41-0.90) 0.01
9 rs4240705 RXRA 136451221 0.77 (0.58-1.04) 0.09
9 rs6537944 RXRA 136452649 0.99 (0.58-1.68) 0.96
9 rs3118571 RXRA 136457999 0.81 (0.61-1.08) 0.14
9 rs4842196 RXRA 136473049 0.94 (0.68-1.30) 0.70
9 rs3118526 RXRA 136477178 0.84 (0.55-1.28) 0.42
11 rs7117967 CYP2R1 14782654 1.07 (0.65-1.76) 0.80
11 rs12419657 CYP2R1 14783385 0.68 (0.41-1.13) 0.14
11 rs1037379 CYP2R1 14809360 1.09 (0.81-1.45) 0.57
11 rs10832306 CYP2R1 14813670 1.05 (0.67-1.63) 0.83
11 rs1496167 CYP2R1 14833083 1.10 (0.82-1.47) 0.51
11 rs11023371 CYP2R1 14852847 1.67 (1.01-2.74) 0.04
11 rs7935792 CYP2R1 14866037 0.99 (0.57-1.74) 0.98
11 rs1792284 DHCR7 70812614 0.86 (0.62-1.18) 0.35
11 rs4316537 DHCR7 70832777 1.35 (0.83-2.19) 0.23
11 rs12785878 DHCR7 70845097 1.01 (0.75-1.36) 0.95
11 rs949178 DHCR7 70877968 1.43 (0.92-2.22) 0.11
11 rs7950649 DHCR7 70898979 0.95 (0.63-1.43) 0.81
12 rs11574143 VDR 46521184 1.24 (0.81-1.90) 0.32
12 rs731236 VDR 46525024 0.91 (0.68-1.21) 0.50
12 rs7975232 VDR 46525104 0.99 (0.75-1.31) 0.96
12 rs1544410 VDR 46526102 0.92 (0.69-1.23) 0.57
12 rs11168268 VDR 46538079 1.01 (0.76-1.33) 0.97
12 rs11574077 VDR 46539194 0.32 (0.12-0.84) 0.02
Supplemental Table 5 - Online Only
12 rs2239182 VDR 46541678 1.14 (0.88-1.49) 0.32
12 rs2107301 VDR 46541837 0.86 (0.63-1.17) 0.34
12 rs2283342 VDR 46542126 0.93 (0.65-1.34) 0.71
12 rs2239179 VDR 46544033 1.12 (0.85-1.47) 0.41
12 rs12717991 VDR 46545393 0.97 (0.74-1.26) 0.81
12 rs886441 VDR 46549231 0.83 (0.58-1.20) 0.32
12 rs2189480 VDR 46550095 0.91 (0.68-1.21) 0.51
12 rs3819545 VDR 46551273 0.94 (0.71-1.25) 0.66
12 rs2239186 VDR 46555677 0.92 (0.66-1.28) 0.62
12 rs10875693 VDR 46555917 1.44 (1.08-1.93) 0.01
12 rs6580642 VDR 46556863 0.84 (0.58-1.24) 0.39
12 rs2254210 VDR 46559981 0.96 (0.73-1.27) 0.80
12 rs2238136 VDR 46563980 1.13 (0.83-1.54) 0.43
12 rs2853564 VDR 46564754 0.91 (0.69-1.22) 0.54
12 rs4760648 VDR 46566932 0.97 (0.74-1.29) 0.86
12 rs11574027 VDR 46573640 1.83 (0.72-4.63) 0.20
12 rs11574026 VDR 46574513 0.70 (0.44-1.11) 0.13
12 rs4760655 VDR 46580398 1.08 (0.81-1.44) 0.59
12 rs7136534 VDR 46580893 0.86 (0.61-1.22) 0.41
12 rs11574024 VDR 46582488 0.84 (0.52-1.36) 0.49
12 rs4516035 VDR 46586093 1.04 (0.78-1.39) 0.77
12 rs11168302 VDR 46598520 1.75 (0.75-4.11) 0.20
12 rs10875702 VDR 46599285 0.82 (0.58-1.17) 0.27
12 rs2269720 CYP27B1 56404515 1.07 (0.79-1.44) 0.68
12 rs4760169 CYP27B1 56405114 1.08 (0.69-1.69) 0.73
12 rs10877011 CYP27B1 56411259 1.03 (0.77-1.38) 0.82
12 rs12368653 CYP27B1 56419523 0.99 (0.75-1.30) 0.94
12 rs1048691 CYP27B1 56439215 0.97 (0.69-1.37) 0.86
12 rs4646537 CYP27B1 56443548 0.61 (0.22-1.66) 0.33
12 rs1021469 CYP27B1 56494431 1.09 (0.81-1.46) 0.57
20 rs2762932 CYP24A1 52201798 1.12 (0.78-1.60) 0.55
20 rs6068810 CYP24A1 52202758 0.91(0.45-1.85) 0.80
20 rs11907350 CYP24A1 52203846 1.25 (0.56-2.80) 0.59
20 rs927650 CYP24A1 52206148 0.98 (0.74-1.29) 0.86
20 rs927651 CYP24A1 52206303 0.98 (0.70-1.36) 0.89
20 rs6097809 CYP24A1 52206917 1.06 (0.59-1.93) 0.84
20 rs1570669 CYP24A1 52207834 0.97 (0.73-1.30) 0.85
20 rs2274130 CYP24A1 52208008 1.01 (0.72-1.40) 0.97
20 rs6127119 CYP24A1 52212489 1.02 (0.72-1.43) 0.93
20 rs6068816 CYP24A1 52214498 0.97 (0.59-1.57) 0.89
20 rs3787555 CYP24A1 52216098 0.91 (0.66-1.24) 0.54
20 rs3787557 CYP24A1 52216542 0.77 (0.51-1.18) 0.23
20 rs2762941 CYP24A1 52217059 1.00 (0.74-1.34) 0.99
20 rs2181874 CYP24A1 52217885 1.01 (0.73-1.39) 0.96
20 rs4809959 CYP24A1 52219266 0.77 (0.59-1.02) 0.07
20 rs4809960 CYP24A1 52219480 0.85 (0.61-1.18) 0.33
20 rs2296241 CYP24A1 52219626 0.80 (0.61-1.06) 0.12
20 rs2245153 CYP24A1 52219813 0.94 (0.67-1.34) 0.74
20 rs2585428 CYP24A1 52220304 1.32 (0.99-1.74) 0.06
20 rs6022999 CYP24A1 52221420 1.13 (0.82-1.54) 0.46
20 rs2248359 CYP24A1 52224925 1.17 (0.88-1.56) 0.27
Abbreviations: CHR, chromosome; SNP, single nucleotide polymorphism; BP, base pair; P, P
value; OR, odds ratio; CI, confidence intervals.
Table 6 (online supplement). Genetic association of SNPs with neovascular AMD adjusted for age,
sex and center
CHR SNP Gene BP OR (95% CI) P
4 rs12512631 GC 72820195 1.05 (0.76-1.43) 0.78
4 rs705117 GC 72826979 0.72 (0.43-1.21) 0.22
4 rs2298850 GC 72833131 1.21 (0.85-1.72) 0.30
4 rs222020 GC 72855136 0.88 (0.56-1.40) 0.60
4 rs1491718 GC 72860143 0.91 (0.54-1.53) 0.72
4 rs1155563 GC 72862352 1.13 (0.79-1.61) 0.50
4 rs16847050 GC 72886195 0.95 (0.58-1.54) 0.82
4 rs1565572 GC 72889055 1.03 (0.69-1.55) 0.88
4 rs11939173 GC 72891022 1.10 (0.79-1.51) 0.58
9 rs11185644 RXRA 136350684 0.53 (0.32-0.87) 0.01
9 rs12339187 RXRA 136369148 0.54 (0.33-0.88) 0.01
9 rs914853 RXRA 136378984 0.87 (0.60-1.24) 0.43
9 rs11185659 RXRA 136383204 0.71 (0.47-1.07) 0.10
9 rs10881582 RXRA 136395899 0.64 (0.43-0.97) 0.04
9 rs7039190 RXRA 136406525 1.21 (0.57-2.58) 0.62
9 rs11103473 RXRA 136427450 0.72 (0.51-1.03) 0.07
9 rs11103482 RXRA 136427681 1.30 (0.80-2.10) 0.29
9 rs3118536 RXRA 136448283 0.54 (0.33-0.87) 0.01
9 rs4240705 RXRA 136451221 0.72 (0.51-1.02) 0.07
9 rs6537944 RXRA 136452649 0.98 (0.53-1.83) 0.96
9 rs3118571 RXRA 136457999 0.78 (0.56-1.10) 0.16
9 rs4842196 RXRA 136473049 0.98 (0.67-1.42) 0.90
9 rs3118526 RXRA 136477178 0.78 (0.47-1.29) 0.33
11 rs7117967 CYP2R1 14782654 0.94 (0.51-1.74) 0.85
11 rs12419657 CYP2R1 14783385 0.66 (0.37-1.20) 0.17
11 rs1037379 CYP2R1 14809360 1.00 (0.71-1.40) 0.99
11 rs10832306 CYP2R1 14813670 0.97 (0.57-1.66) 0.92
11 rs1496167 CYP2R1 14833083 1.10 (0.78-1.54) 0.60
11 rs11023371 CYP2R1 14852847 1.56 (0.88-2.77) 0.13
11 rs7935792 CYP2R1 14866037 1.00 (0.52-1.92) 0.99
11 rs1792284 DHCR7 70812614 0.82 (0.57-1.19) 0.30
11 rs4316537 DHCR7 70832777 1.48 (0.86-2.57) 0.16
11 rs12785878 DHCR7 70845097 0.98 (0.69-1.38) 0.89
11 rs949178 DHCR7 70877968 1.50 (0.91-2.47) 0.12
11 rs7950649 DHCR7 70898979 1.10 (0.69-1.75) 0.68
12 rs11574143 VDR 46521184 1.31 (0.80-2.16) 0.29
12 rs731236 VDR 46525024 0.76 (0.53-1.07) 0.11
12 rs7975232 VDR 46525104 1.08 (0.78-1.48) 0.65
12 rs1544410 VDR 46526102 0.76 (0.54-1.07) 0.12
12 rs11168268 VDR 46538079 1.11 (0.80-1.53) 0.53
12 rs11574077 VDR 46539194 0.18 (0.04-0.76) 0.02
Supplemental Table 6 - Online Only
12 rs2239182 VDR 46541678 1.01 (0.74-1.37) 0.97
12 rs2107301 VDR 46541837 0.98 (0.69-1.40) 0.93
12 rs2283342 VDR 46542126 1.05 (0.70-1.57) 0.83
12 rs2239179 VDR 46544033 1.06 (0.78-1.46) 0.70
12 rs12717991 VDR 46545393 1.07 (0.79-1.45) 0.67
12 rs886441 VDR 46549231 0.77 (0.50-1.20) 0.25
12 rs2189480 VDR 46550095 0.93 (0.66-1.30) 0.66
12 rs3819545 VDR 46551273 1.06 (0.77-1.47) 0.72
12 rs2239186 VDR 46555677 1.05 (0.72-1.53) 0.79
12 rs10875693 VDR 46555917 1.36 (0.97-1.90) 0.08
12 rs6580642 VDR 46556863 0.71 (0.44-1.15) 0.16
12 rs2254210 VDR 46559981 0.98 (0.71-1.36) 0.93
12 rs2238136 VDR 46563980 1.20 (0.84-1.71) 0.33
12 rs2853564 VDR 46564754 0.90 (0.64-1.25) 0.51
12 rs4760648 VDR 46566932 1.01 (0.73-1.39) 0.95
12 rs11574027 VDR 46573640 2.10 (0.73-6.06) 0.17
12 rs11574026 VDR 46574513 0.83 (0.50-1.39) 0.48
12 rs4760655 VDR 46580398 1.13 (0.81-1.58) 0.47
12 rs7136534 VDR 46580893 1.03 (0.70-1.52) 0.88
12 rs11574024 VDR 46582488 0.91 (0.53-1.57) 0.74
12 rs4516035 VDR 46586093 0.91 (0.65-1.27) 0.57
12 rs11168302 VDR 46598520 2.12 (0.82-5.51) 0.12
12 rs10875702 VDR 46599285 0.95 (0.64-1.41) 0.78
12 rs2269720 CYP27B1 56404515 1.10 (0.78-1.56) 0.57
12 rs4760169 CYP27B1 56405114 1.20 (0.72-1.99) 0.49
12 rs10877011 CYP27B1 56411259 1.04 (0.74-1.44) 0.84
12 rs12368653 CYP27B1 56419523 1.04 (0.76-1.44) 0.80
12 rs1048691 CYP27B1 56439215 0.95 (0.63-1.43) 0.81
12 rs4646537 CYP27B1 56443548 0.79 (0.26-2.38) 0.68
12 rs1021469 CYP27B1 56494431 1.13 (0.81-1.58) 0.46
20 rs2762932 CYP24A1 52201798 1.11 (0.73-1.68) 0.63
20 rs6068810 CYP24A1 52202758 0.94 (0.42-2.11) 0.89
20 rs11907350 CYP24A1 52203846 1.68 (0.71-3.97) 0.24
20 rs927650 CYP24A1 52206148 0.94 (0.68-1.30) 0.73
20 rs927651 CYP24A1 52206303 0.98 (0.67-1.44) 0.93
20 rs6097809 CYP24A1 52206917 0.83 (0.39-1.75) 0.62
20 rs1570669 CYP24A1 52207834 0.98 (0.70-1.38) 0.90
20 rs2274130 CYP24A1 52208008 1.02 (0.70-1.50) 0.90
20 rs6127119 CYP24A1 52212489 1.10 (0.74-1.63) 0.64
20 rs6068816 CYP24A1 52214498 1.10 (0.64-1.90) 0.73
20 rs3787555 CYP24A1 52216098 0.92 (0.64-1.33) 0.66
20 rs3787557 CYP24A1 52216542 0.70 (0.42-1.15) 0.16
20 rs2762941 CYP24A1 52217059 1.06 (0.75-1.49) 0.75
20 rs2181874 CYP24A1 52217885 1.04 (0.71-1.51) 0.86
20 rs4809959 CYP24A1 52219266 0.78 (0.56-1.07) 0.12
20 rs4809960 CYP24A1 52219480 0.83 (0.57-1.22) 0.35
20 rs2296241 CYP24A1 52219626 0.84 (0.61-1.16) 0.28
20 rs2245153 CYP24A1 52219813 0.91 (0.61-1.37) 0.65
20 rs2585428 CYP24A1 52220304 1.28 (0.92-1.76) 0.14
20 rs6022999 CYP24A1 52221420 1.24 (0.87-1.78) 0.24
20 rs2248359 CYP24A1 52224925 1.27 (0.91-1.77) 0.16
Abbreviations: CHR, chromosome; SNP, single nucleotide polymorphism; BP, base pair; P, P
value; OR, odds ratio; CI, confidence intervals.